|8.02||+0.0100||+0.12%||Vol 2.13M||1Y Perf 6.23%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||11.25||Analyst Rating||Hold 2.83|
|Potential %||40.27||Finscreener Ranking||☆ 32.16|
|Insiders Trans % 3/6/12 mo.||-/-100/-37||Value Ranking||☆ 33.58|
|Insiders Value % 3/6/12 mo.||-/-100/46||Growth Ranking||+ 30.01|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/45||Income Ranking||— -|
|Price Range Ratio 52W %||52.57||Earnings Rating||Strong Buy|
|Market Cap||2.92B||Earnings Date||2nd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd Nov 2023|
|Estimated EPS Next Report||0.92|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.86M|
|Avg. Monthly Volume||3.23M|
|Avg. Quarterly Volume||2.82M|
Bausch Health Companies Inc. (NYSE: BHC) stock closed at 8.01 per share at the end of the most recent trading day (a -1.6% change compared to the prior day closing price) with a volume of 2.65M shares and market capitalization of 2.92B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 21600 people. Bausch Health Companies Inc. CEO is Joseph C. Papa.
The one-year performance of Bausch Health Companies Inc. stock is 6.23%, while year-to-date (YTD) performance is 27.55%. BHC stock has a five-year performance of -69.77%. Its 52-week range is between 5.5703 and 10.23, which gives BHC stock a 52-week price range ratio of 52.57%
Bausch Health Companies Inc. currently has a PE ratio of 9.70, a price-to-book (PB) ratio of 18.74, a price-to-sale (PS) ratio of 0.45, a price to cashflow ratio of 3.90, a PEG ratio of 0.49, a ROA of 0.99%, a ROC of 1.49% and a ROE of -72.80%. The company’s profit margin is 3.34%, its EBITDA margin is 38.70%, and its revenue ttm is $6.12 Billion , which makes it $16.93 revenue per share.
Of the last four earnings reports from Bausch Health Companies Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.92 for the next earnings report. Bausch Health Companies Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Bausch Health Companies Inc. is Hold (2.83), with a target price of $11.25, which is +40.27% compared to the current price. The earnings rating for Bausch Health Companies Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bausch Health Companies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bausch Health Companies Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.56, ATR14 : 0.29, CCI20 : -118.87, Chaikin Money Flow : -0.05, MACD : -0.10, Money Flow Index : 32.62, ROC : -5.99, RSI : 40.38, STOCH (14,3) : 36.59, STOCH RSI : 0.00, UO : 43.51, Williams %R : -63.41), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bausch Health Companies Inc. in the last 12-months were: Seana Carson (Sold 8 252 shares of value $69 898 )
Wed, 20 Sep 2023 09:07 GMT Bausch Health upgraded to Buy from Hold at Jefferies- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.